FGFR4 and breast carcinoma: Furthermore, Bhatia et al., developed long-term TNBC patient-derived organoids that imitated the extensively studied and evidently proven features of this aggressive MYC-driven, basal-like breast cancer and were largely comprised of luminal progenitor-like cells exhibiting hyperactivation of NOTCH and MYC signaling [27], while Chew et al., described low or undetectable Fibroblast Growth Factor Receptor 4 (FGFR4) immunohistochemical staining in TNBC patient-derived organoids [28].